Liver Cancer News and Research

RSS

Liver cancer is more common in older people. Over half of people newly diagnosed with liver cancer are age 65 and over. Liver cancer is more common in men than in women. Liver cancer rates are highest among Asians and Pacific Islanders, most likely because of higher prevalence of viral Hepatitis infection. Liver cancer rates are lower among whites than Blacks or Asians and Pacific Islanders. At this time, we do not know exactly what causes cancer of the liver. There are several different types of liver cancer. The most common type is associated with long-term excessive alcoholic beverage use, scarring of the liver (cirrhosis), and Hepatitis B virus or Hepatitis C virus infection. Long-term use of anabolic steroids can also increase the risk of getting liver cancer. Smoking is also believed to increase the risk of getting liver cancer.

X-ray irradiation emerges as a new tool to combat aflatoxin-contaminated corn

Corn, a staple food crop consumed by billions of people and animals worldwide, is frequently contaminated by the fungal toxin aflatoxin B1, a highly potent carcinogen produced by the fungus Aspergillus flavus.

16 Aug 2024

Neoadjuvant immunotherapy yields comparable outcomes in high-risk liver cancer surgery

Patients with liver cancer who received immune checkpoint inhibitors (ICIs) before surgery - including those who would not have been eligible for surgery by conventional criteria - had similar outcomes to patients who received surgery upfront, according to results from a retrospective study.

15 Aug 2024

Liver stiffness becomes crucial indicator for post-treatment hepatitis C risk assessment

Hepatitis C can be cured in almost all cases with modern medication. However, if advanced liver damage is already present at the time of cure, there is still a residual risk of liver cancer and complications of portal hypertension, such as abdominal fluid, bleeding from the digestive tract and confusion.

14 Aug 2024

The interplay of liver cancer stem cells and immune cells in tumor microenvironment

The complex dynamics between liver cancer stem cells (CSCs) and immune cells within the tumor microenvironment (TME) are central to the progression of liver cancer. These interactions are critical in creating an immunosuppressive setting that significantly impacts the response to immunotherapy. Liver CSCs, responsible for tumor initiation, metastasis, therapeutic resistance, and recurrence, exhibit heterogeneity and are characterized by various surface markers that contribute to their stemness and metastatic potential.

7 Aug 2024

Rising cancer rates in younger generations signal urgent need for early-life prevention strategies

A study in The Lancet Public Health reveals rising cancer incidence and mortality among younger US birth cohorts, indicating increased early-life carcinogenic exposure.

4 Aug 2024

Study shows growing cancer burden in younger generations

A new large study led by researchers at the American Cancer Society (ACS) suggests incidence rates continued to rise in successively younger generations in 17 of the 34 cancer types, including breast, pancreatic, and gastric cancers.

1 Aug 2024

Review highlights the interplay of TGF-β and HIPPO pathways in liver regeneration and disease

The liver's ability to communicate with other organs is crucial for maintaining homeostasis, particularly through signaling pathways.

30 Jul 2024

Advancing hepatic cell carcinoma treatment through mitochondrial DNA targeting

Hepatic cell carcinoma (HCC), the fifth most prevalent malignancy worldwide and the fourth leading cause of cancer-related mortality, poses significant therapeutic challenges.

29 Jul 2024

Study identifies non-statin cholesterol drugs with potential to lower liver cancer risk

Past studies have suggested that taking cholesterol-lowering statin drugs may lower individuals' risk of developing liver cancer.

29 Jul 2024

Inflammation may not be key to fighting liver fibrosis in MAFLD

Researchers at UCLA Health uncovered new information about the role inflammation plays in mitigating liver fibrosis, which is associated with metabolic-associated fatty liver disease (MAFLD), one of the most common diseases in the world affecting up to 40 percent of U.S. adults. While inflammation in the liver has long been considered a prerequisite to developing liver fibrosis, the scarring and thickening of tissue that can impair the liver's ability to function, this new research suggests that reducing inflammation may not influence the extent of fibrosis.

27 Jul 2024

Saffron: A golden remedy for modern health challenges

Review highlights saffron's potential in preventing and treating various human diseases through its bioactive compounds. Clinical and preclinical studies confirm saffron's benefits in conditions like maculopathy, depression, neurodegenerative diseases, and cancer.

21 Jul 2024

Ultrasound techniques for the surveillance, diagnosis, and treatment of hepatocellular carcinoma

Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and one of the leading causes of cancer-related deaths worldwide. Early detection and accurate diagnosis are crucial for effective management and improved survival rates.

16 Jul 2024

Study: 40% of cancer cases in the U.S. attributable to modifiable risk factors

A new study led by researchers at the American Cancer Society (ACS) finds four in 10 cancer cases and about one-half of all cancer deaths in adults 30 years old and older in the United States (or 713,340 cancer cases and 262,120 cancer deaths in 2019) could be attributed to modifiable risk factors, including cigarette smoking, excess body weight, alcohol consumption, physical inactivity, diet, and infections.

11 Jul 2024

Group of small molecules exclusive to liver tumors could be key to developing cancer vaccines

A study led by the Hospital del Mar Research Institute, with Cima University of Navarra and Pompeu Fabra University, has identified a group of small molecules exclusive to liver tumors that could be key to developing cancer vaccines.

11 Jul 2024

Liver's defense mechanism hinders immunity in chronic hepatitis B, study reveals

In chronic hepatitis B, the liver contains immune cells that could destroy hepatitis B virus infected cells but are inactive. A team from the Technical University of Munich (TUM) has discovered that cells blood vessels in the liver start a "sleep timer" that switches off immune cells. Targeting this mechanism could be a starting point for immunotherapies.

11 Jul 2024

Existing drug shows promise for treating common liver disease

The University of Barcelona has led a study that suggests using the drug known as pemafibrate to treat liver disease associated with metabolic disorders, the most common liver pathology in the world, which affects one in four people. The drug has long been marketed in Japan for another use: improving blood lipid levels in patients with hyperlipidaemia, a common condition in diabetics. Now, however, it could help address this serious liver disease, which still has no specific treatment.

11 Jul 2024

Repurposing pemafibrate to treat liver disease associated with metabolic disorders

10 Jul 2024

Transforming growth factor beta inhibition boosts NK cell therapy against hepatocellular carcinoma

Researchers at University of California San Diego have found that the most common form of liver cancer - one with a high mortality rate - can be better targeted and treated using an innovative new stem cell-derived therapy, according to a recently published study in Cell Stem Cell.

9 Jul 2024

GLP-1 drugs found to lower cancer risk in diabetes patients

Research finds that GLP-1 receptor agonists significantly reduce the risk of 10 out of 13 obesity-associated cancers in type 2 diabetes patients compared to insulins, but show varied results against metformin.

8 Jul 2024

Advancements in immunotherapy for hepatocellular carcinoma offer hope to patients

Hepatocellular carcinoma (HCC) is a primary liver cancer predominantly arising from chronic liver diseases such as hepatitis B and C infections, alcohol abuse, and metabolic disorders.

2 Jul 2024

Liver Cancer News and Research

Further Reading

X-ray irradiation emerges as a new tool to combat aflatoxin-contaminated corn

Neoadjuvant immunotherapy yields comparable outcomes in high-risk liver cancer surgery

Liver stiffness becomes crucial indicator for post-treatment hepatitis C risk assessment

The interplay of liver cancer stem cells and immune cells in tumor microenvironment

Rising cancer rates in younger generations signal urgent need for early-life prevention strategies

Study shows growing cancer burden in younger generations

Review highlights the interplay of TGF-β and HIPPO pathways in liver regeneration and disease

Advancing hepatic cell carcinoma treatment through mitochondrial DNA targeting

Study identifies non-statin cholesterol drugs with potential to lower liver cancer risk

Inflammation may not be key to fighting liver fibrosis in MAFLD

Saffron: A golden remedy for modern health challenges

Ultrasound techniques for the surveillance, diagnosis, and treatment of hepatocellular carcinoma

Study: 40% of cancer cases in the U.S. attributable to modifiable risk factors

Group of small molecules exclusive to liver tumors could be key to developing cancer vaccines

Liver's defense mechanism hinders immunity in chronic hepatitis B, study reveals

Existing drug shows promise for treating common liver disease

Repurposing pemafibrate to treat liver disease associated with metabolic disorders

Transforming growth factor beta inhibition boosts NK cell therapy against hepatocellular carcinoma

GLP-1 drugs found to lower cancer risk in diabetes patients

Advancements in immunotherapy for hepatocellular carcinoma offer hope to patients

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News